Country for PR: United States
Contributor: PR Newswire New York
Tuesday, November 15 2022 - 23:30
Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis
ANNAPOLIS, Md., Nov. 15, 2022 /PRNewswire-AsiaNet/ --

Alphyn Biologics ( 
), a clinical-stage dermatology company developing first-in-class multi-target 
therapeutics, announced today that it has completed the first cohort of its 
Phase2a clinical trial of AB-101a, a topical therapeutic candidate for 
mild-to-moderate atopic dermatitis (AD) in adults and children as young as 2 
years old. The first cohort enrolled AD patients without bacterial infection, 
which is sometimes associated with the disease. Top-line results are expected 
in approximately eight weeks.

Logo -

The randomized, vehicle-controlled, double-blind trial is evaluating the 
treatment protocol of AB-101a across multiple sites using standard scales for 
assessing AD. Enrollment is ongoing in a second cohort of the trial, which 
uniquely is investigating the treatment in AD patients who are also suffering 
from bacterial infections, including staphylococcus aureus, or Staph, and MRSA, 
the antibiotic-resistant Staph. Alphyn anticipates AB-101a will be effective 
against non-infected AD and infected AD and expects it will offer patients and 
physicians a comprehensive, safe, and convenient treatment option.

AB-101a was developed using Alphyn's proprietary AB-101 platform. The platform 
has multiple bioactive compounds and, therefore, multiple mechanisms of action 
to potentially address multiple problems of any target disease. Alphyn began 
its clinical trial program in Phase 2 due to the strong safety profile of its 
AB-101 platform.


Alphyn Biologics is a clinical-stage dermatology company developing 
first-in-class multi-target therapeutics for severe and prevalent skin diseases 
based on its AB-101 platform. Its lead product candidate, AB-101a, is being 
developed as a topical treatment for atopic dermatitis (AD), the most common 
form of eczema. AB-101a has demonstrated a strong safety profile and is in 
development to uniquely target AD's immune system and bacterial components, 
making it ideal for treating non-infected and infected AD. Alphyn's AB-101 
platform has multiple bioactive compounds and therefore multiple mechanisms of 
action to support a robust pipeline of dermatologic therapeutics that have 
potential safety, efficacy and regulatory marketing authorization advantages. 
Alphyn is based in Annapolis, Maryland and Cincinnati, Ohio, and has a wholly 
owned Australia subsidiary. The company became operational in 2020 and has 
raised approximately $6.9 million.

CONTACT: Corporate, Neal Koller,, (410) 690-8687; 
Media, Susan Thomas,, (619) 540-9195

SOURCE:  Alphyn Biologics